



Mylan – Recall of levoleucovorin

- On February 1, 2019, [Mylan announced](#) a voluntary recall of two lots of [levoleucovorin](#) injection due to the presence of sub-visible particulate matter exceeding the specification.
- The recalled lots were distributed between August 2017 and July 2018.

Product Description	NDC#	Lot# (Expiration Date)
Levoleucovorin injection 250 mg/25 mL, 10 mL vial	67457-601-30	APB032 (4/2019); APB033 (4/2019)

- Levoleucovorin is indicated for rescue after high-dose methotrexate therapy in osteosarcoma; to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; and for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.
- Per Mylan, intravenous administration of a solution containing particulates could lead to local irritation, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism.
- To date, Mylan has not received any reports of adverse events related to this recall.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled levoleucovorin.
- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.
- For more information regarding this recall, contact Stericycle (appointed company for Mylan) at **1-866-551-2706**.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.